Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 30
Posts 27,019
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Ecb Holds Firm On Rates Despite Recent Data
The European Central Bank kept interest rates unchanged at record lows as officials wait to see if aggressive stimulus measures announced in June and September are enough to boost inflation and provide a lift to the eurozone's fragile economy.
More Top Equities Stories Of The Day
Bank of America Board Gives Chairman Job to Brian Moynihan
JAL Customer Data Target of Cyber Attack
IPO Scorecard: Update on Selected Initial Stock Offerings
Europe Stocks Stay Low, Euro Steady -- 2nd Update
Intel Invests in Chinese Chip Maker -- Update
Bank Branches in U.S. Decline to Lowest Level Since 2005
Starboard Pushes For Potential Yahoo-AOL Tie-Up -- 5th Update
Starboard Pushes For Potential Yahoo-AOL Tie-Up -- 5th Update
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68263 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist